4Moving Biotech, a biotechnology company and subsidiary of 4P-Pharma, focusing on the development of 4P004, a first-in-class disease modifying osteoarthritis drug (DMOAD) for a curative treatment of osteoarthritis, announces that it has enrolled its first patient for phase I of LASARE clinical trial study.

“We are so excited to have the first patient enrolled in our first-in-human phase 1 clinical study. […] we hope to bring a unique first-in-class solution to improve quality of life for the millions of people suffering from OA worldwide”, said Francis Berenbaum, co-founder and CEO/CMO of 4Moving Biotech, Professor of rheumatology at Sorbonne University and Head of rheumatology department at St-Antoine’s hospital (AP-HP) in Paris.

Read the full press release on Business Wire.



Contact presse

Emmanuelle Lopez – CFO

Email : emmanuelle.lopez@4p-pharma.com

Emmanuel Dadjé – Communication Service

E-mail : emmanuel.dadje@4p-pharma.com

Office : + 33 1 44 97 40 59